Blair William & CO Tg Therapeutics, Inc. Transaction History

Blair William & CO

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 13, 2022	SELL	$7.81 - $20.45 $78,100 - $204,500	-10,000 Closed	0 $0
Q3 2021 Nov 12, 2021	SELL	$21.78 - $40.45 $27,225 - $50,562	-1,250 Reduced 11.11%	10,000 $333,000
Q2 2021 Aug 12, 2021	BUY	$32.5 - $48.96 $32,500 - $48,960	1,000 Added 9.76%	11,250 $436,000
Q4 2020 Feb 09, 2021	SELL	$25.27 - $54.9 $379,050 - $823,500	-15,000 Reduced 59.41%	10,250 $533,000
Q2 2020 Aug 12, 2020	BUY	$8.9 - $21.84 $135,725 - $333,060	15,250 Added 152.5%	25,250 $492,000
Q1 2020 May 11, 2020	BUY	$7.14 - $15.99 $71,400 - $159,900	10,000 New	10,000 $98,000

338

88.3M

2.35M

1.7M

Ticker TGTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 145,274,000
Market Cap $4.29B
Description
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...

Get notified when there are updates to the investment portfolio of Blair William & CO, based on Form 13F filings with the SEC.

Stay updated on Blair William & CO with notifications on news.